Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Molecular Oncology
|
June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
Rodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
The Oncologist
|
February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
British Journal of Cancer
|
September 4, 2019
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
Mª Pilar Solis-Hernandez, Ana Fernandez Del Valle, Alberto Carmona-Bayonas, et al.
Cancer Research Communications
|
May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancer
Martha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
European Journal of Endocrinology
|
July 9, 2017
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila, José Manuel Trigo, Javier Aller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Molecular Oncology
|
June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
Rodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
The Oncologist
|
February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
British Journal of Cancer
|
September 4, 2019
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
Mª Pilar Solis-Hernandez, Ana Fernandez Del Valle, Alberto Carmona-Bayonas, et al.
Cancer Research Communications
|
May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancer
Martha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
European Journal of Endocrinology
|
July 9, 2017
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila, José Manuel Trigo, Javier Aller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Page
of 4